Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 0.48 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | AVPR1B | P47901 | 3/20 | 0.37 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
| ▸ | CTRC | Q99895 | 1/20 | 0.37 |
| ▸ | GPR6 | P46095 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4962113 | 0.93 | BACE1 (0.51) | BACE1HRH2HRH3CCR2 | |
| Trifluoroacetic Acid SCHEMBL4246805 | 0.85 | BACE1 (0.40) | BACE1HRH2HRH3CCR2 | |
| Trifluoroacetic Acid SCHEMBL4245400 | 0.79 | BACE1 (0.51) | BACE1AVPR1BCMA1CTRCGPR6 | |
| SCHEMBL4247361 | 0.76 | BACE1 (0.46) | BACE1HRH2HRH3CCR2 | |
| Trifluoroacetic Acid SCHEMBL4250441 | 0.75 | BACE1 (0.57) | BACE1AVPR1BCMA1CTRC | |
| Trifluoroacetic Acid SCHEMBL4242602 | 0.73 | BACE1 (0.55) | BACE1CMA1CTRC | |
| Trifluoroacetic Acid SCHEMBL4245228 | 0.72 | BACE1 (0.56) | BACE1CMA1CTRC | |
| SCHEMBL8237695 | 0.70 | BACE1 (0.50) | BACE1HRH2HRH3 | |
| SCHEMBL4247343 | 0.69 | BACE1 (0.39) | BACE1 | |
| SCHEMBL8239238 | 0.66 | BACE1 (0.62) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215801-A9 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB, SODERTAIJE, SWEDENASTEX THEREAPEUTICS LTD (GB) | 2009-08-27 | — | — | US | claimed |
| US-20080255164-A1 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | claimed |
| US-20090215801-A9 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB, SODERTAIJE, SWEDENASTEX THEREAPEUTICS LTD (GB) | 2009-08-27 | — | — | US | disclosed |
| US-20080255164-A1 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215801-A9 | Novel 2-Aminopyrimidinone Derivatives And Their Use | PSEN2, PSEN1, MAPT | BACE1 9/4885HRH2 1709/4885HRH3 2038/4885 |
| US-20080255164-A1 | Novel 2-Aminopyrimidinone Derivatives And Their Use | PSEN2, PSEN1, MAPT | BACE1 9/4885HRH2 1709/4885HRH3 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.